Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
Displaying: 2,323 trials in your specialties ()
View trials across your selected specialties

Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Iron Deficiency Anemia, Anemia
View Full Trial
INTERVENTION

Drug: Ferrous Sulfate 300Mg Tablet, Drug: Vitamin C 500Mg tablet

Eligibility
  • Ages: 16 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Brief Summary

Iron deficiency anemia is a global health problem and the most common cause of anemia worldwide. Patients with iron deficiency (ID) and IDA can present with a multitude of symptoms including fatigue, restless legs syndrome and pica.Oral iron supplementation is associated with increasing hemoglobin in multiple studies in women, pregnant women and elderly patients.However, the optimal dose and frequency of oral iron supplementation for treatment remains unclear. The current proposed study attempts to address this gap in the literature.

Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Veno-occlusive Disease
View Full Trial
INTERVENTION

Drug: Defibrotide, Other: Best Supportive Care

Eligibility
  • Ages: 1 Month and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Children's Hospital of Alabama, Birmingham, Alabama, United States

Brief Summary

This study is to compare the efficacy and safety of defibrotide prophylaxis in addition to best supportive care versus best supportive care alone in the prevention of hepatic veno- occlusive disease (VOD) in adult and pediatric patients undergoing hematopoietic stem cell transplant who are at high risk or very high risk of developing VOD.

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell
View Full Trial
INTERVENTION

Biological: Alemtuzumab (Campath), Drug: EPOCH

Eligibility
  • Ages: 17 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Brief Summary

Background: The paradigm of combining therapeutic agents with non-overlapping toxicities for the treatment of malignancy produces clinical remissions and cures in a number of tumor types. A new class of agents, humanized and chimerized monoclonal antibodies, typically have little or no hematopoietic toxicity and can be readily combined with full doses of cytotoxic chemotherapy. It has become clear that in certain lymphomas and breast cancers, the combination of monoclonal antibodies and chemotherapy improves response rate and the quality of the response compared with that achieved by treatment with either agent alone. The clinical outcome for patients with T-cell non-Hodgkins lymphoma is significantly inferior to the outcome of patients with B-cell non-Hodgkin s lymphoma. In most reports less than 20% of patients with T cell lymphoid malignancies remain free of disease at 5 years. Objectives: Determine the toxicity of Alemtuzumab and etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) chemotherapy in untreated cluster of differentiation 52 (CD52)-expressing T and natural killer (NK) lymphoid malignancies. Determine the maximum tolerated dose of Alemtuzumab administered in combination with EPOCH chemotherapy. Determine in a preliminary fashion the anti-tumor activity of the combination of Alemtuzumab and EPOCH chemotherapy. Eligibility: CD52-expressing lymphoid malignancy. Patients with chemotherapy naive aggressive T & NK lymphomas. Patients with alk-positive anaplastic large cell lymphoma and patients with T cell precursor disease are not eligible. Age greater than or equal to 17 years. Adequate organ function, unless impairment due to respective organ involvement by tumor. No active symptomatic ischemic heart disease, myocardial infarction or congestive heart. failure within the past year. Human immunodeficiency virus (HIV) negative. Not pregnant or nursing. Design: Three dose levels of Alemtuzumab will be evaluated to determine the toxicity profile and in a preliminary fashion the antitumor activity of the combination with Dose-Adjusted EPOCH. Three dose levels of Alemtuzumab will be explored, in cohorts of three to six patients each. Patients will receive either 30, 60, or 90 mg of Alemtuzumab on day 1 of therapy, followed by dose-adjusted EPOCH chemotherapy days 1-5.

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Generalized Lipodystrophy
View Full Trial
INTERVENTION

Drug: Placebo, Drug: Low-Dose REGN4461, Drug: High-dose REGN4461

Eligibility
  • Ages: 12 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Regeneron Research Facility, Ann Arbor, Michigan, United States

Brief Summary

The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on fasting triglyceride levels in the subset of patients with elevated baseline fasting triglycerides (TG ≥250 mg/dL). The secondary objectives are to estimate the effects of REGN4461 on a composite endpoint of changes in either HbA1c or fasting TG for all patients, estimate the effects of 2 dose levels of REGN4461 on glycemic parameters and fasting TG, to estimate the effects of REGN4461 on insulin sensitivity, to evaluate the safety and tolerability of REGN4461 and to evaluate the pharmacokinetics (PK) and immunogenicity of REGN4461.

Confirmatory Study of BK1310 in Healthy Infants

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Pertussis, Poliomyelitis, Bacterial Meningitis, Tetanus, Diphtheria
View Full Trial
INTERVENTION

Biological: DPT-IPV-Hib, Biological: Hib vaccine, Biological: DPT-IPV

Eligibility
  • Ages: 2 to 42 Months (Child)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Investigational Site, Fukuoka-shi, Fukuoka, Japan

Brief Summary

The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with co-administration of ActHIB® and Tetrabik, as well as efficacy and safety, in healthy infants.

Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) and Acquired Angioedema (AAE) Due to C1-INH Deficiency

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Angioedema
View Full Trial
INTERVENTION

Drug: Lanadelumab, Other: Placebo

Eligibility
  • Ages: 12 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Clinical Research Center of Alabama, Birmingham, Alabama, United States

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of repeated subcutaneous (SC) administrations of lanadelumab in preventing angioedema attacks in adolescents and adults with non-histaminergic angioedema with normal C1-INH and in adults with acquired angioedema (AAE) due to C1-INH deficiency.

A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Non Hodgkin Lymphoma
View Full Trial
INTERVENTION

Drug: R-CHOP + acalabrutinib

Eligibility
  • Ages: 16 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Southampton University Hospitals NHS Tust, Southampton, Hampshire, United Kingdom

Brief Summary

Previously untreated CD20 positive diffuse large B-cell lymphoma (DLBCL) requiring full course chemoimmunotherapy.

Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Untreated Childhood Medulloblastoma, Untreated Childhood Pineobla...
View Full Trial
INTERVENTION

Radiation: 3-Dimensional Conformal Radiation Therapy, Drug: Carboplatin, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Etoposide Phosphate, Drug: Isotretinoin, Other: Laboratory Biomarker Analysis, Procedure: Peripheral Blood Stem Cell Transplantation, Drug: Thiotepa, Drug: Vincristine Sulfate, Drug: Vorinostat

Eligibility
  • Ages: 2 to 47 Months (Child)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Children's Hospital Los Angeles, Los Angeles, California, United States

Brief Summary

This pilot clinical trial studies the side effects and the best way to give vorinostat with isotretinoin and combination chemotherapy and to see how well they work in treating younger patients with embryonal tumors of the central nervous system. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as isotretinoin, vincristine sulfate, cisplatin, cyclophosphamide, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vorinostat with isotretinoin and combination chemotherapy may be an effective treatment for embryonal tumors of the central nervous system. A peripheral blood stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed.

CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    CD19+ Malignancies: Relapse Post-allogeneic Transplant
View Full Trial
INTERVENTION

Genetic: Infusion of modified CAR19 T-cells (4G7-CARD T-cells)

Eligibility
  • Ages: 16 to 70 Years (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University College London Hospital, London, United Kingdom

Brief Summary

Eligible patients will receive escalating doses of 4G7-CARD T-cells paralleling clinical standard of care with unmanipulated donor lymphocytes. There are 3 intra-patient dose levels planned. Patients will be followed up regularly during the interventional phase of the study until 12 months post-final 4G7-CARD T-cell infusion. Thereafter patients will be followed up annually for years 2 and 3.

Study of Ataluren in Participants With Nonsense Mutation Aniridia

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Aniridia
View Full Trial
INTERVENTION

Drug: Ataluren, Drug: Placebo

Eligibility
  • Ages: 2 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States

Brief Summary

This study is designed to evaluate the effect of ataluren on Maximum Reading Speed as measured using the Minnesota Low Vision Reading Test (MNREAD) Acuity Charts in participants with nonsense mutation aniridia. This study involves a 4-week screening period, a 144-week treatment period (Stage 1: Weeks 1 to 48 [double-masked treatment] and Stage 2: Weeks 49 to 144 [open label treatment]), an optional 96-week open label extension sub-study, and a 4-week post-treatment follow-up period (either study completion or early termination). Participants that choose not to participate in the sub-study will be required to complete the post-treatment follow-up visit at the end of the Stage 2 open-label extension.